See more : Baumart Holdings Limited (BMH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Morphic Holding, Inc. (MORF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morphic Holding, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kyodo Printing Co., Ltd. (7914.T) Income Statement Analysis – Financial Results
- Huhtamaki India Limited (HUHTAMAKI.NS) Income Statement Analysis – Financial Results
- Perpetua Resources Corp. (PPTA) Income Statement Analysis – Financial Results
- CDN Maverick Capital Corp. (CDN.CN) Income Statement Analysis – Financial Results
- Howden Joinery Group Plc (HWDJY) Income Statement Analysis – Financial Results
Morphic Holding, Inc. (MORF)
About Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 521.00K | 70.81M | 19.79M | 44.95M | 16.98M | 3.36M | 0.00 |
| Cost of Revenue | 1.09M | 1.00M | 1.03M | 73.63M | 53.73M | 22.63M | 434.00K |
| Gross Profit | -570.00K | 69.80M | 18.76M | -28.69M | -36.76M | -19.27M | -434.00K |
| Gross Profit Ratio | -109.40% | 98.58% | 94.80% | -63.82% | -216.50% | -573.94% | 0.00% |
| Research & Development | 140.38M | 102.06M | 87.79M | 73.63M | 53.73M | 22.63M | 14.10M |
| General & Administrative | 38.82M | 32.14M | 27.81M | 18.50M | 10.23M | 5.36M | 2.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 32.14M | 27.81M | 18.50M | 10.23M | 5.36M | 2.83M |
| Other Expenses | 2.00K | -145.00K | -8.00K | -19.00K | -94.00K | -74.00K | -5.00K |
| Operating Expenses | 179.21M | 134.20M | 115.60M | 92.13M | 63.97M | 27.99M | 16.93M |
| Cost & Expenses | 179.21M | 134.20M | 115.60M | 92.13M | 63.97M | 27.99M | 16.93M |
| Interest Income | 26.97M | 4.57M | 272.00K | 1.63M | 4.67M | 871.00K | 14.00K |
| Interest Expense | 0.00 | 4.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.09M | 1.00M | 1.03M | 1.13M | 821.00K | 539.00K | 434.00K |
| EBITDA | -177.60M | -62.39M | -94.78M | -46.05M | -46.17M | -24.09M | -16.50M |
| EBITDA Ratio | -34,087.33% | -89.53% | -484.02% | -104.97% | -271.94% | -717.36% | 0.00% |
| Operating Income | -178.69M | -63.40M | -95.81M | -47.18M | -46.99M | -24.63M | -16.93M |
| Operating Income Ratio | -34,296.74% | -89.53% | -484.02% | -104.97% | -276.77% | -733.41% | 0.00% |
| Total Other Income/Expenses | 26.97M | 4.42M | 264.00K | 1.61M | 4.57M | 797.00K | 9.00K |
| Income Before Tax | -151.72M | -58.97M | -95.54M | -45.57M | -42.42M | -23.83M | -16.92M |
| Income Before Tax Ratio | -29,119.96% | -83.29% | -482.68% | -101.39% | -249.84% | -709.68% | 0.00% |
| Income Tax Expense | 380.00K | 67.00K | -1.30M | -570.00K | 912.00K | 797.00K | -14.00K |
| Net Income | -152.10M | -59.04M | -94.24M | -45.00M | -43.33M | -23.83M | -16.92M |
| Net Income Ratio | -29,192.90% | -83.38% | -476.10% | -100.12% | -255.22% | -709.68% | 0.00% |
| EPS | -3.59 | -1.55 | -2.63 | -1.47 | -1.44 | -1.04 | -0.74 |
| EPS Diluted | -3.59 | -1.55 | -2.63 | -1.47 | -1.44 | -1.04 | -0.74 |
| Weighted Avg Shares Out | 42.39M | 38.11M | 35.80M | 30.59M | 30.15M | 22.89M | 22.89M |
| Weighted Avg Shares Out (Dil) | 42.39M | 38.11M | 35.80M | 30.59M | 30.19M | 22.89M | 22.89M |
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Morphic to Participate in March Investor Conferences
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
Best Momentum Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports